A randomized controlled trial analyzing nonthermal atmospheric plasma for the treatment of verruca vulgaris in pediatric patients.

IF 12.8 1区医学 Q1 DERMATOLOGY Journal of the American Academy of Dermatology Pub Date : 2025-01-01 Epub Date: 2024-08-27 DOI:10.1016/j.jaad.2024.07.1522

Courtney L Walker, Chelsea N Shope, Laura A Andrews, Kelly M Atherton, Tyler Beck, Gabriella Santa Lucia, Gregory Fridman, Peter C Friedman, Colleen H Cotton, Lara Wine Lee

{"title":"A randomized controlled trial analyzing nonthermal atmospheric plasma for the treatment of verruca vulgaris in pediatric patients.","authors":"Courtney L Walker, Chelsea N Shope, Laura A Andrews, Kelly M Atherton, Tyler Beck, Gabriella Santa Lucia, Gregory Fridman, Peter C Friedman, Colleen H Cotton, Lara Wine Lee","doi":"10.1016/j.jaad.2024.07.1522","DOIUrl":null,"url":null,"abstract":"Background: Verruca vulgaris (VV) is a common viral disease in children. Treatment options are often not well tolerated in children due to pain or adverse effect risk. Nonthermal atmospheric plasma (NTAP), which generates reactive oxygen/nitrogen species, is well tolerated and without adverse effects.Objective: Determine efficacy of NTAP as compared to standard of care (SOC) therapy for VV in children.Methods: This prospective open-label study randomized lesions 1:1 to receive NTAP or SOC (cryotherapy). Patients were treated at 4-week intervals for a maximum of 3 treatments. They were evaluated 4 weeks postfinal treatment for sustained response. Primary outcome was lesion response.Results: One hundred twelve VV lesions in 14 patients were enrolled. Patients were mostly White (92.9%) males (71.4%) with mean age of 9.5 [±2.5] years. Responses of SOC- and NTAP-treated lesions, respectively, included no response (5.4%, 7.1%); partial response (33.9%, 41.1%); and complete resolution (60.7%, 51.8%; P value = .679). Patients were more likely to report pain in SOC lesions post-treatment (P value <.001). No significant adverse events (AEs) occurred.Limitations: Limitations include single-site, maximum of 3 treatments, and short post-treatment follow-up.Conclusion: NTAP is an efficacious, safe intervention for treatment of VV in children.","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":"46-50"},"PeriodicalIF":12.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Academy of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jaad.2024.07.1522","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/27 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Verruca vulgaris (VV) is a common viral disease in children. Treatment options are often not well tolerated in children due to pain or adverse effect risk. Nonthermal atmospheric plasma (NTAP), which generates reactive oxygen/nitrogen species, is well tolerated and without adverse effects.

Objective: Determine efficacy of NTAP as compared to standard of care (SOC) therapy for VV in children.

Methods: This prospective open-label study randomized lesions 1:1 to receive NTAP or SOC (cryotherapy). Patients were treated at 4-week intervals for a maximum of 3 treatments. They were evaluated 4 weeks postfinal treatment for sustained response. Primary outcome was lesion response.

Results: One hundred twelve VV lesions in 14 patients were enrolled. Patients were mostly White (92.9%) males (71.4%) with mean age of 9.5 [±2.5] years. Responses of SOC- and NTAP-treated lesions, respectively, included no response (5.4%, 7.1%); partial response (33.9%, 41.1%); and complete resolution (60.7%, 51.8%; P value = .679). Patients were more likely to report pain in SOC lesions post-treatment (P value <.001). No significant adverse events (AEs) occurred.

Limitations: Limitations include single-site, maximum of 3 treatments, and short post-treatment follow-up.

Conclusion: NTAP is an efficacious, safe intervention for treatment of VV in children.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

分析非热大气等离子体治疗小儿疣的随机对照试验

背景：寻常疣（VV）是儿童常见的病毒性疾病。由于疼痛或不良反应风险，儿童往往不能很好地接受治疗方案。非热大气等离子体（NTAP）能产生活性氧/氮物种，耐受性好且无不良反应：确定 NTAP 与标准疗法（SOC）治疗儿童 VV 的疗效：这项前瞻性开放标签研究以 1:1 的比例随机分配病例接受 NTAP 或 SOC（冷冻疗法）治疗。患者每隔 4 周接受一次治疗，最多治疗 3 次。最后一次治疗后四周，对患者的持续反应进行评估。主要结果是病变反应：14名患者的112个VV病灶被纳入研究。患者多为白人（92.9%）、男性（71.4%），平均年龄为 9.5 [±2.5] 岁。SOC和NTAP治疗病灶的反应分别包括：无反应（5.4%，7.1%）；部分反应（33.9%，41.1%）；完全缓解（60.7%，51.8%；P值=0.679）。患者更有可能在治疗后报告 SOC 病灶疼痛（p-value）：限制因素包括治疗部位单一、最多治疗三次以及治疗后随访时间短：结论：NTAP 是治疗儿童 VV 的一种有效、安全的干预方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of the American Academy of Dermatology 医学-皮肤病学

CiteScore

8.60

自引率

5.80%

发文量

2023

审稿时长

49 days

期刊介绍： The Journal of the American Academy of Dermatology (JAAD) is the official scientific publication of the American Academy of Dermatology (AAD). Its primary goal is to cater to the educational requirements of the dermatology community. Being the top journal in the field, JAAD publishes original articles that have undergone peer review. These articles primarily focus on clinical, investigative, and population-based studies related to dermatology. Another key area of emphasis is research on healthcare delivery and quality of care. JAAD also highlights high-quality, cost-effective, and innovative treatments within the field. In addition to this, the journal covers new diagnostic techniques and various other topics relevant to the prevention, diagnosis, and treatment of skin, hair, and nail disorders.